Anticoagulant status under COVID-19: The potential pathophysiological mechanism

Abstract

Coronavirus disease 19 (COVID-19) is a systematic multitropic disease. Sustaining blood homeostasis is a mission of multiple factors includes procoagulant and anticoagulant systems. Subsequently, maintaining a precise equilibrium between these antagonists' systems is crucial to prevent hemostasis. Frequently, during severe forms of COVID-19 patients, studies reported a discrepancy between the procoagulant and anticoagulant that usually results in fatal outcomes through multiorgan ischemia by thrombotic events. The proper interpreting of the anticoagulant status changes in COVID-19 patients is sufficient for effective and safe anticoagulant treatment. Our postulation is the first to address the pathophysiology of anticoagulant status under COVID-19.

Keywords

• anticoagulant
• coagulopathy
• coronavirus disease 19
• hemostasis
• homeostasis
• pathogenesis
• pulmonary embolism
• severe acute respiratory syndrome coronavirus disease 2
• thrombosis